A5101458223- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Esophageal Cancer Research and Treatment
- AI in cancer detection
- Calcium signaling and nucleotide metabolism
- Digital Radiography and Breast Imaging
- Breast Lesions and Carcinomas
- CNS Lymphoma Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Ovarian cancer diagnosis and treatment
- Gallbladder and Bile Duct Disorders
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Endometriosis Research and Treatment
- Epigenetics and DNA Methylation
- Hepatocellular Carcinoma Treatment and Prognosis
- Endometrial and Cervical Cancer Treatments
- Inflammatory Biomarkers in Disease Prognosis
- Monoclonal and Polyclonal Antibodies Research
- Uterine Myomas and Treatments
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
Guangdong Medical College
2024
Jiangsu University
2012-2024
Affiliated Hospital of Jiangsu University
2018-2024
Karolinska Institutet
2024
Zhumadian Central Hospital
2023
Tianjin Medical University Cancer Institute and Hospital
2010-2023
Zhejiang University
2014-2021
Second Affiliated Hospital of Zhejiang University
2017-2021
Merck & Co., Inc., Rahway, NJ, USA (United States)
2015-2021
Hangzhou First People's Hospital
2018-2021
Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines first-line treatment of EGJ recommend chemotherapy containing a platinum and fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated gastroesophageal cancer. Aim: To describe the design rationale randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate...
The KEYNOTE-013 study was conducted to evaluate pembrolizumab monotherapy in hematologic malignancies; classical Hodgkin lymphoma (cHL) an independent expansion cohort. We present long-term results based on >4 years of median follow-up for the cHL trial enrolled patients who experienced relapse after, were ineligible for, or declined autologous stem cell transplantation and progression with did not respond brentuximab vedotin. Patients received IV 10 mg/kg every 2 weeks up until confirmed...
8005 Background: PD-1 blockade via pembro monotherapy showed antitumor activity in R/R cHL. KEYNOTE-204 (NCT02684292) was a randomized, international, open-label, phase III study of vs BV Methods: Patients (pts) were aged ≥18 y, post−autologous stem cell transplant (auto-SCT) or ineligible for auto-SCT, and had measurable disease ECOG PS 0 1. BV-naive BV-exposed pts eligible. Pts randomized 1:1 to 200 mg IV Q3W 1.8 mg/kg stratified by prior auto-SCT (yes no) status after 1L therapy (primary...
The identification of predictive biomarkers and novel targets to optimize immunotherapy strategies for epithelial ovarian cancer (EOC) is urgently needed. CD38 a multifunctional glycoprotein that acts as an ectoenzyme immune receptor. However, the underlying immunological mechanisms prognostic value in EOC remain unclear. gene expression was evaluated by using Gene Expression Profiling Interactive Analysis (GEPIA) TISIDB database. calculated GEPIA Kaplan-Meier plotter. set enrichment...
Angiogenesis is an essential physiological process and hallmark of cancer. Currently, antiangiogenic therapy, mostly targeting the vascular endothelial growth factor (VEGF)/VEGFR2 signaling axis, commonly used in clinic for solid tumors. However, therapies breast cancer patients have produced limited survival benefits since cells rapidly resistant to anti-VEGFR2 therapy. We applied low-dose high-dose VEGFR2 mAb or VEGFR2-tyrosine kinase inhibitor (TKI) agents multiple mouse models found that...
The automated breast ultrasound system (ABUS) is a potential method for cancer detection; however, its diagnostic performance remains unclear. We conducted hospital-based multicenter study to evaluate the clinical of ABUS detection by comparing it handheld (HHUS) and mammography (MG).Eligible participants underwent HHUS testing; women aged 40-69 years additionally MG. Images were interpreted using Breast Imaging Reporting Data System (BI-RADS). Women in BI-RADS categories 1-2 considered...
Neuroendocrine tumors are rare in the ovary. Definitive epidemiologic and prognostic information for neuroendocrine carcinoma of ovary is lacking. This retrospective population-based study aimed to elucidate demographic clinicopathologic characteristics ovary.Patients with diagnosed between January 1994 December 2014were identified from Surveillance, Epidemiology, End Results (SEER) database National Cancer Institute. Cancer-specific survival was calculated by Kaplan-Meier plots comparisons...
The aim of this study is to determine pathological factors that increase the risk LNM and indicate poor survival patients diagnosed with endometrial cancer treated surgical staging.Between January 2010 November 2018, we enrolled 874 eligible who received staging surgery in First Affiliated Hospital Anhui Medical University. roles prognostic factors, such as age, histological subtype, tumor grade, myometrial infiltration, diameter, cervical lymphopoiesis space invasion (LVSI), CA125, ascites,...
TPS6589 Background: The PD-1 inhibitor pembrolizumab is currently approved as first-line monotherapy for patients with R/M HNSCC whose tumors express PD-L1 combined positive score (CPS) ≥1. In a phase 1b/2 trial (NCT02501096) of plus lenvatinib (multikinase VEGFR 1-3, FGFR 1-4, PDGFRa, RET, and KIT) in solid tumors, the combination demonstrated promising antitumor activity manageable safety profile HNSCC. LEAP-010 (NCT04199104) randomized, double-blind, placebo-controlled, 3 study that will...
KEYNOTE-204 (NCT02684292) demonstrated a progression-free survival advantage for pembrolizumab over brentuximab vedotin (BV) in patients who had relapsed or refractory classical Hodgkin lymphoma (R/R cHL) following, were ineligible for, autologous stem cell transplantation (ASCT). Health-related quality of life (HRQoL), measured by patient-reported outcomes (PROs) from KEYNOTE-204, are reported received ≥1 dose study treatment and completed PRO assessment. The EORTC QoL Questionnaire Core 30...
Objectives Adenomyosis is a common and refractory disease in gynecology. Preserving the uterus during treatment for adenomyosis remains problem. High-intensity focused ultrasound (HIFU) widely used of solid tumors. This study aimed to analyze patients with who were treated by HIFU preliminarily examine characteristics are more suitable treat reliable efficacy. Methods Over 2 years, 67 women diagnosed at our gynecology department included this study. We investigated outcomes their symptoms...
The changes of blood perfusion contralateral testis after unilateral testicular torsion remain controversial. In this study, 28 New Zealand white male rabbits were randomly divided into five groups. Group A (n = 8), the control group, underwent a sham operation on without inducing torsion. groups B, C, and D 5 each), was induced, and, 3, 6 or 24 h, respectively, detorsion performed. group E 5), permanent applied. Contrast-enhanced ultrasound used to observe at following stages: pre-torsion...
Retinal artery occlusion caused by myxoma is relatively rare. There are several points that should be taken into consideration to avoid overlooking this disorder. This case report describes a 43-year-old woman with sudden vision loss in her left eye for 20 days after single syncope. Fundus examination of the showed obscure boundary optic disc with, reflective dispersion retina and poor light reflex central fovea. A retinal was found eye. Echocardiography revealed tumor atrium. Visual...